Daratumumab (DARA) is a targeted therapy for multiple myeloma. It is an antibody to CD38, which is present on plasma cells and red blood cells. Therapy with daratumumab can cause an interference with blood compatibility testing if the drug binds to the reagent red cells of the panel used for antibody testing.
